News

24 June 2026
Efferon on ESPNIC 2026
22 April 2026
Efferon®NEO Receives CE MDR Mark
10 April 2026
Efferon at ISICEM
08 April 2026
Efferon first distributors meeting
11 March 2026
Efferon is now available in Poland
26 February 2026
Efferon®LPS is available in Costa Rica
18 February 2026
Efferon®LPS is now approved in Thailand
10 December 2025
Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis
25 November 2025
We’ll see each other in Greece
05 November 2025
Efferon therapies are now available in Armenia!
30 October 2025
Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis
18 October 2025
Efferon LPS has been approved in the Kingdom of Saudi Arabia.
09 October 2025
Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable
05 October 2025
Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok
12 September 2025
Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn
23 July 2025
Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.
01 July 2025
Efferon LPS Now Available in Italy
28 June 2025
Applying Vicenza’s Lessons
23 June 2025
Efferon Expands Its Global Presence
06 June 2025
Efferon expands to new markets with Bertossi partnership
25 May 2025
Efferon LPS becomes available in Romania.
22 July 2024
New distribution agreements in European countries
29 April 2024
Efferon LPS receives CE mark under EU MDR
20 April 2023
Results of LASSO mRCT are published in Shock
03 November 2022
Efferon at LIVES 2022 in Paris
30 November 2021
Efferon has participated in MEDICA
22 October 2020
Conferences in Moscow
29 April 2021
LASSO multicenter randomized trial launched
31 March 2021
Shipment to Latin America
General Reanimatology. 2025;21(6):4–12.
Multimodal LPS-selective hemoadsorption combined with hemodiafiltration in the intensive care of gram-negative sepsis: a multicenter observational study.
ESICM LIVES 2025. ICMx 13 (Suppl 1), 109 (2025).
Efferon LPS NEO hemoadsorption in pediatric sepsis patients: a multicenter controlled study
Critical Care 2024, 28(Suppl 1):P220
Hemoperfusion with Efferon LPS NEO device reverts multiple organ failure, decreases IL-6 and TNF levels and systemic immune inflammation in children with sepsis
Shock. 2023 Jun 1;59(6):846-854
Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial
Intensive Care Medicine Experimental 2022, 10(2): 000710
Extracorporeal hemoperfusion with Efferon LPS for rapid reconstitution of vital parameters and decreasing proinflammatory biomarkers in patients with intra-abdominal sepsis
World Journal of Medical Case Reports. Vol. 2, No. 3, 2021, pp. 46-50.
Application of novel device Efferon LPS in hemoperfusion for simultaneous removal of endotoxin and cytokines in a patient with septic shock
Therapeutic archive. 2021; 93 (7): 811-817
Extracorporeal adsorption of cytokines in cytokine release syndrome in a patient with acute lymphoblastic leukemia after therapy with T cells with a chimeric antigen receptor. Clinical observation
General resuscitation. 2020; 16 (6): 31-53.
Application of adsorbent based on a hypercrosslinked styrene-divinylbenzene copolymer with an immobilized LPS-selective ligand in hemoperfusion for the treatment of patients with septic shock
General resuscitation. 2020; 16 (4): 14-20.
Hemosorption carried out by a column filled with hypercrosslinked styrene-divinibenzene copolymer with an immobilized LPS-selective ligand in a complex of intensive treatment of acute lung injury in the surgical treatment of lung cancer (clinical observation)
General resuscitation. 2018; 14 (6): 51-60.
Efficiency and safety of a new product for LPS-selective hemosorption (experimental study)
Publications